Skip to main content

Investigating how tumour microenvironment supports immune evasion

29 Oct 2024
Clinical Development
  • How will targeting the tumor microenvironment open new avenues for drug development?
  • What does the significant, yet transient, activity of immunotherapy for CNS tumors tell us about targeting this set of diseases?
  • What discovery platforms and data sets will provide the best leads for developing immunotherapies that surmount negative tumor microenvironments?
  • How can we layer new immunotherapies onto the successes seen with immune check-point blockade?
Industry Experts
Rimas Orentas, Scientific Director - Caring Cross